Go to the list of all blogs
M. Benett's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
Why Is DocGo Inc. (DCGO) Stock Down -9.06% Today?

Why Is DocGo Inc. (DCGO) Stock Down -9.06% Today?

Key Takeaways

  • DCGO shares fell 9.06% to $0.1888 on Monday, down $0.0188 from Friday's close of $0.2076 and a new 52-week low.
  • No company press release, SEC filing, analyst action or wire report was identified for Monday's session to account for the drop.
  • The decline extends the post-earnings slide that began after third-quarter results on Nov. 9 missed on both revenue and earnings and management cut full-year revenue guidance to about $300 million.
  • Secondary drivers: a CEO transition announced alongside the quarter, thin liquidity with $19.1 million of unrestricted cash, and a sub-$1 share price that keeps Nasdaq listing-compliance risk in focus.
  • Trading remains stock-specific, with no sector-wide catalyst identified; the shares sit far below their 50-day (~$0.31) and 200-day (~$0.54) moving averages.
  • News Significance Score: 30/100 — moderate, week-old fundamental news amplified by a large but familiar micro-cap swing.
  • What traders are watching next: closure of the Hicuity Health acquisition expected in late November or early December, progress toward fourth-quarter breakeven, and any word from the board's CEO search.
  • For deeper detail on DCGO, explore Price Targets, Earnings, and Forecast pages.
  • Readers can also review Trending AI Robots for a live view of top-performing automated strategies.

Opening Summary

DocGo Inc. (DCGO) is a New York-based provider of technology-enabled mobile health services and medical transportation, operating ambulance and non-emergency transport fleets alongside mobile phlebotomy, remote patient monitoring and virtual care through a 50-state clinician network. The company serves municipalities, hospital systems and insurers, and generates roughly $300 million in annual revenue.

In Monday's session, the stock traded at $0.1888, a decline of $0.0188, or 9.06%, from the prior close of $0.2076. The direction is unambiguously negative, and the price marks a fresh 52-week low for the micro-cap, whose market capitalization has slipped to roughly $19 million. No verified catalyst specific to Monday's session was found; the move extends a downtrend that accelerated after the company's third-quarter report.

No verified news or fundamental catalyst found for Monday's session

No verified news or fundamental catalyst found for Monday's trading. No regulatory filing, financing announcement, contract loss or analyst revision accompanied the decline. The most defensible reading is that the selling is a continuation of the post-earnings repricing that began on Nov. 9, reinforced by the mechanics of a sub-$1, thinly traded equity.

Impulse and momentum effects are consistent with the evidence: the shares have now fallen in four of the last five sessions, dropping from $0.2518 on Nov. 9 to $0.1888, a loss of about 25%. For a stock this small, quoted spreads are wide and order books shallow, so modest sell interest can produce outsized percentage moves without any new information.

Post-Earnings Overhang and a Cut Price Target

The fundamental backdrop remains the November quarter. DocGo reported revenue of $73.4 million, up 3.7% year over year but below consensus of roughly $77 million, and a GAAP net loss of $0.17 per share against an expected loss of about $0.04. Management trimmed 2026 revenue guidance to approximately $300 million from $305–$310 million, citing the deliberate elimination of unprofitable contracts, while reaffirming a full-year adjusted EBITDA loss of $17–$22 million.

The company also disclosed that chief executive Lee Bienstock will step down once a successor is named, with his contract expiring Dec. 31 and an executive search underway. One sell-side firm cut its price target to $1 from $3 while keeping a Buy rating, citing the guidance reduction and the leadership change. With unrestricted cash of $19.1 million at quarter-end and a fresh $12.5 million debt tranche drawn in October, the market's focus has shifted decisively from growth to runway.

Listing Compliance and Deal Risk

The shares have traded below $1 since early 2026, keeping the company exposed to Nasdaq's minimum bid-price requirement and the possibility of a reverse split or other remedial step. Adding to the uncertainty is the pending acquisition of virtual-care provider Hicuity Health, expected to close in late November or early December and excluded from current guidance. Investors are weighing whether the deal adds scale or leverage, and each session without resolution has tended to favor sellers.

Market Context and Trading Activity

Volume in the name has been running above its longer-run norm: the 30-day average is roughly 700,000 shares versus about 514,000 across the last 60 sessions, a pattern typical of heavy liquidation in a falling micro-cap. The move diverged from broad healthcare and transport benchmarks, which is consistent with company-specific selling rather than sector rotation.

Technically, the picture is weak. The stock is roughly 40% below its 50-day moving average and about 65% below its 200-day average, with Monday's price undercutting the prior 52-week floor of $0.207. There is no nearby support level of consequence from recent trading, and the shares are down more than 80% over twelve months.

News Significance Score

The score runs from 0, meaning no meaningful news and an ordinary move for the stock, to 100, meaning transformative news and an extreme, rare price move. DocGo's score is 30 out of 100.

The verified news is real but not new: an earnings miss, a guidance cut, a CEO transition and a reduced price target amount to moderate-to-material news for a company of this size, though the market has had a week to digest it. The price move was about 2.2 times the stock's typical absolute daily move of roughly 4% over the last 60 sessions, and swings of this magnitude occurred six times in that window. Familiar volatility and stale news combine into a modest score.

What Comes Next for DCGO

Attention now turns to the Hicuity Health closing and whether the combined business delivers the promised revenue contribution in 2027. Fourth-quarter results, expected in March, will be scrutinized for evidence that the adjusted EBITDA loss closes toward breakeven after the $3.2 million third-quarter shortfall, and for cash burn after the October financing. The board's CEO search remains an open variable, as does any Nasdaq compliance update. Risks include further contract exits, margin pressure in mobile health, delayed deal closing and the possibility that liquidity becomes the dominant narrative. Analysts currently carry a Buy consensus, though targets remain far above the market price.

Trending AI Robots

Tickeron's Trending AI Robots page curates the strongest automated strategies operating in current market conditions, drawn from a library of hundreds of AI trading bots that cover thousands of tickers. Bots differ widely by strategy logic, holding timeframe, performance metrics and the symbols they trade, so the featured list changes as conditions shift. It is a practical starting point for investors who want to see which automated approaches are working right now — worth a look alongside your own research.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: DCGO

DCGO's RSI Oscillator stays in oversold zone for 1 day

It is expected that a price bounce should occur soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +3.37% 3-day Advance, the price is estimated to grow further. Considering data from situations where DCGO advanced for three days, in 186 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.

DCGO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DCGO as a result. In 77 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.

The Moving Average Convergence Divergence Histogram (MACD) for DCGO turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 43 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DCGO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for DCGO entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.204) is normal, around the industry mean (204.532). P/E Ratio (-0.126) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.154) among similar stocks. P/S Ratio (0.127) is also within normal values, averaging (2.688).

The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. DCGO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DCGO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

Notable companies

The most notable companies in this group are DaVita (NYSE:DVA), Community Health Systems (NYSE:CYH), WW International Inc (NASDAQ:WW).

Industry description

Hospital/Nursing Management companies own and operate health care facilities. Their operations include nursing homes, acute care facilities, retirement centers and outpatient surgery centers. HCA Healthcare Inc., Alcon Inc. and Universal Health Services, Inc. are some major companies in this industry. Technology has been at the forefront of development of advanced solutions, including quicker diagnoses of complex conditions. Investments in new diagnostics, healthcare IoT, and other healthcare technologies continue to gather momentum in this industry.

Market Cap

The average market capitalization across the Hospital/Nursing Management Industry is 5.37B. The market cap for tickers in the group ranges from 20.9K to 107.17B. HCA holds the highest valuation in this group at 107.17B. The lowest valued company is NMMCF at 20.9K.

High and low price notable news

The average weekly price growth across all stocks in the Hospital/Nursing Management Industry was -10%. For the same Industry, the average monthly price growth was -7%, and the average quarterly price growth was 3%. AUNA experienced the highest price growth at 4%, while BMGL experienced the biggest fall at -83%.

Volume

The average weekly volume growth across all stocks in the Hospital/Nursing Management Industry was -25%. For the same stocks of the Industry, the average monthly volume growth was 52% and the average quarterly volume growth was -2%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 47
Price Growth Rating: 54
SMR Rating: 66
Profit Risk Rating: 82
Seasonality Score: -5 (-100 ... +100)
Trend Prediction Engine 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry HospitalNursingManagement

Industry
N/A
Address
685 Third Avenue
Phone
+1 844 443-6246
Employees
3568
Web
https://www.docgo.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.